Flatiron Health at ASH 2023: The future of hematologic cancer research
Visit us at booth #3156
At ASH 2023, we are honored to present our research as part of a global scientific forum driving progress in hematologic oncology and evidence generation, focusing on:
-
Advanced AI methodologies, such as machine learning and natural language processing. These applications allow us to access unstructured data for clinical research, match eligible patients to clinical trials, accelerate oncology drug development, and address timely research questions as the standard of care changes, particularly for complex and rare diseases.
-
Advancing health equity and diversity in clinical trials leveraging real-world data to enhance the representativeness of hematologic malignancy clinical trials and generate insights into diverse patient populations, supporting FDA-mandated diversity plans and advancing all aspects of health equity research.
Our unwavering commitment to innovative research drives us to enhance healthcare outcomes for people with cancer, continuing to use data for good to reimagine the infrastructure of cancer care.
Featured webinar
Innovative approaches to evidence generation that unlock key insights in hematologic cancer
The drug development landscape is rapidly evolving with FDA-mandated Diversity Plans and AI methodologies shaping evidence generation for hematologic malignancies. RWE and clinical trial solutions are vital in advancing trial diversity and accelerating the process.
Explore these changes with Flatiron Health experts in this panel discussion on evidence solutions in hematologic drug development.
Moderator
Jenna Collins, MPH
Director, Scientific Engagement
Flatiron Health
Aaron Cohen, MD, MSCE
Medical Director II
Flatiron Health
Amy Pierre, MSN, RN, ANP-BC
Senior Clinical Director
Flatiron Health
Cleo A. Ryals, PhD
Senior Director, Head of Health Equity
Flatiron Health
Read more about our accepted research at this year’s conference
Oral presentation
Retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma
Author affiliations: University of Texas Southwestern Medical Center, University of Washington, Mayo Clinic, Flatiron Health
Most induction regimens for multiple myeloma contain bortezomib, usually given twice a week according to frequencies used in clinical trials. However, single-center studies and secondary analysis from a phase-III trial suggest once-weekly dosing is effective with reduced side effects, leading to its adoption by some doctors. This study explores the real-world usage and effectiveness of once-weekly versus twice-weekly bortezomib, addressing this knowledge gap.
Connect with a
flatiron expert
Xiaoliang (Wendy) Wang, PhD, MPH
Senior Quantitative Scientist
Connect on LinkedIn
Oral presentation
Clinical characteristics, treatment trends, and outcomes of patients with HHV-8-negative/idiopathic multicentric Castleman disease treated with siltuximab in a machine learning-selected real-world cohort
Author affiliations: NYU School of Medicine, University of Pennsylvania, and Flatiron Health
In this study, researchers utilized machine learning to analyze treatment and survival data of patients with rare HHV-8-negative/idiopathic multicentric Castleman disease from a nationwide EHR database, addressing gaps in real-world outcomes
Oral presentation
Performance of newer staging systems for myeloma in a contemporary, large cohort of patients in the United States
Author affiliations: Huntsman Cancer Institute, Lineberger Comprehensive Cancer Center, Mayo Clinic, Flatiron Health
The most widely used multiple myeloma staging system, R-ISS, lacks accounting for additional risk from genetic abnormalities or Gain1q presence. Two newer staging systems (MASS and R2-ISS) were proposed, incorporating these risks into the classification process. This study externally validates these systems in a large, contemporary US patient cohort and compares their performance.
poster presentation
Low socioeconomic status confers poorer-real-world overall survival for patients with acute myeloid leukemia treated in the modern era
Author affiliations: University of Southern California and Flatiron Health
This real-world study examines recent trends in survival among an overall population of over 10,000 people with AML, and across demographic and socioeconomic subgroups, amidst the rapidly changing treatment armamentarium.
Connect with a
flatiron expert
Mark Guinter, MPH, PhD
Senior Quantitative Scientist
Connect on LinkedIn
poster presentation
Inequities in autologous stem cell transplantation, chimeric antigen receptor T-cell therapy and clinical trial participation in patients receiving second-line and later multiple myeloma treatment
Author affiliations: University of California, Berkeley, Memorial Sloan Kettering Cancer Center, University of Southern California, and Flatiron Health
This study investigates inequities in advanced multiple myeloma treatments, including salvage therapies and new drugs. It assesses patients' receipt of ASCT, CAR-T, and participation in clinical trials after initiating second-line treatment, aiming to identify community-level inequities based on race, ethnicity, and sociodemographic factors.
poster presentation
Multi-level factors underlying racial/ethnic inequities in clinical trial participation among patients with hematologic cancers: lessons for the development of diversity planning
Author affiliations: University of California, Berkeley, Memorial Sloan Kettering Cancer Center, University of Southern California, and Flatiron Health
Starting in 2024, clinical trials reviewed by the FDA will be required to include diversity action plans. This requirement recognizes that people from racial and ethnic minority groups face inequities in access to participation in clinical research. In this study, we investigated how common trial criteria and social factors contribute to racial/ethnic inequities in clinical trial participation across six hematologic cancers.
